Literature DB >> 27663039

Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.

Osama W Amro1, Jessica K Paulus2, Farzad Noubary2, Ronald D Perrone3.   

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) affects millions of people worldwide. Vasopressin promotes disease progression. STUDY
DESIGN: A randomized controlled trial with equal (1:1) allocation. SETTING & PARTICIPANTS: This trial examined the effect of combining a low-osmolar (low-sodium [1,500mg/d], low-protein [0.8g per kilogram of body weight]) diet and adjusted water intake on vasopressin secretion in 34 patients with ADPKD. INTERVENTION: Participants were randomly assigned to receive a low-osmolar diet followed by adjusted water intake to achieve urine osmolality ≤ 280mOsm/kg water versus no intervention for 2 weeks. OUTCOME: The primary outcome of the study was change (delta) in copeptin levels and urine osmolality between the intervention and control groups from baseline to 2 weeks. MEASUREMENTS: Fasting plasma copeptin level, 24-hour urine osmolality, and total solute intake.
RESULTS: Baseline characteristics of the 2 groups were similar. Mean plasma copeptin levels and urine osmolality declined from 6.2±3.05 (SD) to 5.3±2.5pmol/L (P=0.02) and from 426±193 to 258±117mOsm/kg water (P=0.01), respectively, in the intervention group compared to a nonsignificant change in the control group (from 4.7±3.6 to 5.07±4pmol/L [P=0.2] and 329±159 to 349±139mOsm/kg water [P=0.3], respectively). The change in copeptin levels (primary outcome) and urine osmolality was statistically significant between the intervention and control groups (delta copeptin, -0.86±1.3 vs +0.39±1.2pmol/L [P=0.009]; delta urine osmolality, -167±264 vs +20±80mOsm/kg water [P=0.007], respectively). Total urinary solute decreased in only the intervention group and significantly differed between groups at week 1 (P=0.03), reducing mean water prescription from 3.2 to 2.6L/d. LIMITATIONS: Small sample size and short follow-up.
CONCLUSIONS: We developed a stepwise dietary intervention that led to a significant reduction in vasopressin secretion in patients with ADPKD. Furthermore, this intervention led to a reduction in water required for vasopressin reduction.
Copyright © 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease (ADPKD); clinical trial; copeptin; nutrition; osmolality; protein; salt; urea; vasopressin; water

Mesh:

Substances:

Year:  2016        PMID: 27663039      PMCID: PMC5123924          DOI: 10.1053/j.ajkd.2016.07.023

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  31 in total

1.  The precision of estimating protein intake of patients with chronic renal failure.

Authors:  Tahsin Masud; Amita Manatunga; George Cotsonis; William E Mitch
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

2.  Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids.

Authors:  Paula Trumbo; Sandra Schlicker; Allison A Yates; Mary Poos
Journal:  J Am Diet Assoc       Date:  2002-11

3.  Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States.

Authors:  Sandrina Balanescu; Peter Kopp; Mary Beth Gaskill; Nils G Morgenthaler; Christian Schindler; Jonas Rutishauser
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

4.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Authors:  Connie J Wang; Catherine Creed; Franz T Winklhofer; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

5.  Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

Authors:  Shizuko Nagao; Kazuhiro Nishii; Makoto Katsuyama; Hiroki Kurahashi; Tohru Marunouchi; Hisahide Takahashi; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2006-06-28       Impact factor: 10.121

6.  Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.

Authors:  R D Perrone; R Ruthazer; N C Terrin
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

7.  Stimulatory effect of caffeine on the hypothalamo-pituitary-adrenocortical axis in the rat.

Authors:  S A Nicholson
Journal:  J Endocrinol       Date:  1989-08       Impact factor: 4.286

8.  The clinical utility of renal concentrating capacity in polycystic kidney disease.

Authors:  P A Gabow; W D Kaehny; A M Johnson; I T Duley; M Manco-Johnson; D C Lezotte; R W Schrier
Journal:  Kidney Int       Date:  1989-02       Impact factor: 10.612

Review 9.  The medicinal use of water in renal disease.

Authors:  Connie J Wang; Jared J Grantham; James B Wetmore
Journal:  Kidney Int       Date:  2013-02-20       Impact factor: 10.612

10.  Vasopressin directly regulates cyst growth in polycystic kidney disease.

Authors:  Xiaofang Wang; Yanhong Wu; Christopher J Ward; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2007-11-21       Impact factor: 10.121

View more
  16 in total

1.  Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Lauren Pickel; Ioan-Andrei Iliuta; James Scholey; York Pei; Hoon-Ki Sung
Journal:  Adv Nutr       Date:  2021-11-10       Impact factor: 8.701

2.  Conivaptan and Boric Acid Treatments in Acute Kidney Injury: Is This Combination Effective and Safe?

Authors:  Betül Can; Fatih Kar; Ezgi Kar; Mete Özkoç; Hakan Şentürk; Dilek Burukoğlu Dönmez; Güngör Kanbak; İbrahim Özkan Alataş
Journal:  Biol Trace Elem Res       Date:  2021-10-21       Impact factor: 3.738

3.  The relationship between depression, anxiety, quality of life levels, and the chronic kidney disease stage in the autosomal dominant polycystic kidney disease.

Authors:  Aysenur Miray Yarlioglu; Ebru Gok Oguz; Ayse Gokcen Gundogmus; Kadir Gokhan Atilgan; Hatice Sahin; Mehmet Deniz Ayli
Journal:  Int Urol Nephrol       Date:  2022-10-02       Impact factor: 2.266

Review 4.  Nutritional therapy in autosomal dominant polycystic kidney disease.

Authors:  Biagio R Di Iorio; Adamasco Cupisti; Claudia D'Alessandro; Antonio Bellasi; Vincenzo Barbera; Luca Di Lullo
Journal:  J Nephrol       Date:  2018-01-17       Impact factor: 3.902

Review 5.  A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Authors:  Fouad T Chebib; Ronald D Perrone; Arlene B Chapman; Neera K Dahl; Peter C Harris; Michal Mrug; Reem A Mustafa; Anjay Rastogi; Terry Watnick; Alan S L Yu; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2018-09-18       Impact factor: 10.121

6.  Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).

Authors:  Annette T Y Wong; Carly Mannix; Jared J Grantham; Margaret Allman-Farinelli; Sunil V Badve; Neil Boudville; Karen Byth; Jessie Chan; Susan Coulshed; Marie E Edwards; Bradley J Erickson; Mangalee Fernando; Sheryl Foster; Imad Haloob; David C H Harris; Carmel M Hawley; Julie Hill; Kirsten Howard; Martin Howell; Simon H Jiang; David W Johnson; Timothy L Kline; Karthik Kumar; Vincent W Lee; Maureen Lonergan; Jun Mai; Philip McCloud; Anthony Peduto; Anna Rangan; Simon D Roger; Kamal Sud; Vincent Torres; Eswari Vilayur; Gopala K Rangan
Journal:  BMJ Open       Date:  2018-01-21       Impact factor: 2.692

7.  Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey.

Authors:  Ragada El-Damanawi; Tess Harris; Richard N Sandford; Fiona E Karet Frankl; Thomas F Hiemstra
Journal:  Clin Kidney J       Date:  2017-02-17

Review 8.  Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease.

Authors:  Melissa A Cadnapaphornchai
Journal:  Front Pediatr       Date:  2017-03-23       Impact factor: 3.418

9.  Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.

Authors:  Ragada El-Damanawi; Michael Lee; Tess Harris; Laura B Mader; Simon Bond; Holly Pavey; Richard N Sandford; Ian B Wilkinson; Alison Burrows; Przemyslaw Woznowski; Yoav Ben-Shlomo; Fiona E Karet Frankl; Thomas F Hiemstra
Journal:  BMJ Open       Date:  2018-05-09       Impact factor: 2.692

10.  Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease.

Authors:  Steven Soroka; Ahsan Alam; Micheli Bevilacqua; Louis-Philippe Girard; Paul Komenda; Rolf Loertscher; Philip McFarlane; Sanjaya Pandeya; Paul Tam; Daniel G Bichet
Journal:  Can J Kidney Health Dis       Date:  2018-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.